Table 4.
Survival analysis for patients with intraductal carcinoma of the prostate (IDC-P) diagnosed between 2000 and 2020 undergoing radical prostatectomy (RP) ± adjuvant radiotherapy or EBRT only
| Treatment | Summary stage (count) | Five-year survival [95% CI] | Ten-year survival [95% CI] | ||
|---|---|---|---|---|---|
| Cause-specific | Overall | Cause-specific | Overall | ||
| RP | Local (216) | 99% [99%,101%] | 97% [94%,100%] | 98% [95%,100%] | 90% [85%,96%] |
| Regional (216) | 95% [92%,99%] | 93% [89%,97%] | 89% [83%,95%] | 77% [68%,86%] | |
| RP + Adjuvant RT | Local (10) | 100% | 100% | 100% | 80% [44%,116%] |
| Regional (49) | 89% [78%,99%] | 86% [75%,98%] | 69% [51%,87%] | 67% [49%,85%] | |
| EBRT-only | Local (74) | 100% | 92% [85%,100%] | 85% [68%,102%] | 57% [39%,76%] |
| Regional (20) | 71% [46%,96%] | 71% [46%,96%] | 71% [46%,96%] | 71% [46%,96%] | |
Patients with distant disease were excluded from this analysis. Further investigation into the survival for those with regional disease treated solely with EBRT, no patients died between 5 and 10 years after diagnosis, resulting in the same survival (CSS and OS) being calculated